RxDoctor Payments Data

Harvey Green, MD

Psychiatry · Minneapolis, MNNPI 1518023829

Payments from drug & device makers

$464in general payments, 2019–2025

Across 25 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$173
  • Ironshore Pharmaceuticals Inc.$51
  • Neurocrine Biosciences, Inc.$48
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$41
  • Vanda Pharmaceuticals Inc.$36
  • Corium, LLC$28
  • plus $88 from 5 others

What the payments were for

  • Food & beverage$45999%
  • Education$51%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$464 in reported general payments places this provider in the 85th percentile of 552 psychiatry providers in Minnesota.

See all psychiatry providers in Minnesota

Medicare billing

Part B allowed, 2024
$20,091
Medicare patients
30
Services billed
163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AtivanLorazepam13$81,712
VraylarCariprazine Hcl31$57,607
LybalviOlanzapine/Samidorphan Malate20$33,619
RexultiBrexpiprazole19$25,731
CaplytaLumateperone Tosylate13$23,865
BelsomraSuvorexant43$18,722
Lurasidone Hcl39$9,788
SuboxoneBuprenorphine Hcl/Naloxone Hcl11$9,064
VyvanseLisdexamfetamine Dimesylate23$8,926
TrintellixVortioxetine Hydrobromide11$7,729
DayvigoLemborexant20$7,123
Lisdexamfetamine Dimesylate18$4,301
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine55$3,955
Paliperidone ErPaliperidone12$2,722
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine93$2,628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$173$25,73119 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$41$23,86513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 552 psychiatry providers in Minnesota.

Other psychiatry in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →